RxDoctor Payments Data

Jeffrey Shapiro, MD

Internal Medicine · Anaheim, CANPI 1760588776

Payments from drug & device makers

$58,699in general payments, 2019–2025

Across 151 payments — averaging $388.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$37K
  • Portola Pharmaceuticals, LLC$6K
  • E.r. Squibb & Sons, L.L.C.$6K
  • Pfizer$3K
  • Paratek Pharmaceuticals, Inc.$2K
  • Mallinckrodt Hospital Products Inc.$2K
  • plus $3K from 11 others

What the payments were for

  • Consulting fees$5,5749%
  • Speaking & faculty fees$44,61076%
  • Travel & lodging$2,9265%
  • Food & beverage$5,57710%
  • Education$120%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$58,699 in reported general payments places this provider in the 95th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$126,728
Medicare patients
319
Services billed
1,070

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Omeprazole-Sodium BicarbonateOmeprazole/Sodium Bicarbonate35$69,127
Diflorasone Diacetate57$42,364
EliquisApixaban87$38,886
Alcohol Prep PadsAlcohol Antiseptic Pads154$22,824
JardianceEmpagliflozin39$17,114
JanuviaSitagliptin Phosphate27$10,221
XareltoRivaroxaban15$8,752
MyrbetriqMirabegron21$7,453
TradjentaLinagliptin29$6,730
TrintellixVortioxetine Hydrobromide13$6,602
Lacosamide17$5,975
Comfort Ez Pen NeedlePen Needle, Diabetic37$3,494
Pantoprazole Sodium221$3,064
Tamsulosin Hcl199$2,855
Atorvastatin Calcium315$2,800

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$2,759$38,88687 claims
Johnson & JohnsonXarelto$17$8,75215 claims
Astellas Pharma US IncMyrbetriq$44$7,45321 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Anaheim

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →